| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.1 | 0.08 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.058 | 0.08 |
| mRNA | SB-431542 | CTRPv2 | pan-cancer | AAC | 0.067 | 0.08 |
| mRNA | Bosutinib | CTRPv2 | pan-cancer | AAC | -0.061 | 0.08 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.1 | 0.08 |
| mRNA | YM-155 | GDSC1000 | pan-cancer | AAC | -0.057 | 0.08 |
| mRNA | Docetaxel | gCSI | pan-cancer | AAC | -0.098 | 0.08 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.094 | 0.08 |
| mRNA | Gemcitabine | CTRPv2 | pan-cancer | AAC | -0.058 | 0.08 |
| mRNA | ML320 | CTRPv2 | pan-cancer | AAC | -0.062 | 0.09 |